Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in Chinese adults and adolescents with giant cell tumor of bone
NCT04586660Phase 4Active, not recruiting
- Sponsor
- Amgen
- Start
- Aug 2023
- Primary completion
- Mar 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of denosumab in Giant Cell Tumor of Bone (GCTB), sponsored by Amgen. Started Aug 2023; status: active, not recruiting.
02
Drugs
denosumab
03
Conditions
Giant Cell Tumor of Bone (GCTB)
Beyond the preview
Go deeper on NCT04586660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586660.